Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$20MCash on Hand
4.5mo Cash Runway
Follow VTGN by emailGet an email when VTGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VTGN, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 9, 2026 ·
Regulatory Following a Type C meeting, the FDA gave feedback on a Phase 3 path for fasedienol in social anxiety disorder, including interim assessments and a revised protocol. Vistagen plans to focus on the general SAD population rather than acute treatment alone. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Restructuring Vistagen reduced its workforce by about 31% on October 26, 2026, retaining capabilities for Phase 3 development of fasedienol for social anxiety disorder. The company expects about $1.0 million in severance costs and about $3.2 million in annual salary and benefit savings. Form 8-K · SEC filing
Oct 9, 2026 ·
Leadership Vistagen's board amended and restated its Executive Severance Plan on October 7, 2026, effective that day. Severance now applies to termination without Cause outside a change in control, and executive officers are Eligible Employees. Form 8-K · SEC filing
Sep 25, 2026 ·
Vistagen began using a new corporate presentation dated September 2026, furnished as Exhibit 99.1 under Regulation FD. The filing itself reports no trial results, financing, or regulatory decision. Form 8-K · SEC filing · Press release
Sep 24, 2026 ·
Clinical trial Vistagen presented exploratory fasedienol data at Psych Congress 2026 showing a statistically significant SUDS benefit in very severe social anxiety patients (LSAS 95 or higher) in a post-hoc analysis of PALISADE-4, which missed its primary endpoint overall. Form 8-K · SEC filing · Press release
Sep 22, 2026 ·
Clinical trial Reported preliminary open-label extension data from PALISADE-4: 322 patients had no new drug-related safety findings over up to 12 months. Mean LSAS improvement reached 31.4 points by Month 4, and the company plans an FDA meeting this quarter. Form 8-K · SEC filing · Press release
Sep 11, 2026 ·
Shareholder vote Vistagen stockholders re-elected four directors, including CEO Shawn K. Singh, approved executive pay on an advisory basis, and ratified KPMG LLP as auditor for fiscal year ending March 31, 2027. Votes were held September 10, 2026. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2026 · Phase 2 · Results Expected · A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder Registry primary completion date, not a results date
Apr 2026 · Phase 3 · Results Expected · Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) Registry primary completion date, not a results date
Oct 2025 · Phase 3 · Results Expected · Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Registry primary completion date, not a results date
Dec 2022 · Phase 2 · Results Expected · PH94B in the Treatment of Adjustment Disorder With Anxiety Registry primary completion date, not a results date
Jun 2022 · Phase 3 · Results Expected · PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge Registry primary completion date, not a results date
Oct 2019 · Phase 2 · Results Expected · AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
VTGN holds $20M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.4M/quarter from operations,
an estimated runway of 4.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:87 · High
Cash runway 4 months +40
ATM program on file since Jun 2025 +15
Shelf registration (S-3, Feb 2024) +10
Going-concern doubt in the latest 10-Q +15The mitigating effects of management’s plans, however, are only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the consolidated financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant…10-Q, Nov 2026
Share count 46,186,049 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full VTGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.